Titles
- Associate Professor, Faculty of Pharmacy, Université de Montréal
- Co-Director, Montreal Cancer Consortium
- Co-Holder, Jean-Guy Sabourin Chair
- Researcher at the CRCHUM
- Research member at the Montreal Cancer Institute
Research Angle
My laboratory has identified the CD73 enzyme, which generates extracellular adenosine, as a novel therapeutic target in immuno-oncology. We are studying the role of the adenosinergic pathway in oncology. We also study the mechanisms of resistance to anti-PD-1/L1 therapies.
Laboratory Team
- Bertrand Allard, Ph.D., research associate
- Sandra Pommey, M.Sc., research associate
- Isabelle Cousineau, Ph.D., research assistant
- Yacine Bareche, Ph.D., postdoctoral fellow
- David Allard, Ph.D. Student
- Chloé Thivierge, animal health technician
LinkedIn Profile
www.linkedin.com/in/john-stagg-3b164b9
Recent Publications
- https://www.nature.com/articles/s41571-020-0382-2
- https://science.sciencemag.org/content/369/6510/1481.long
- https://jitc.bmj.com/lookup/pmidlookup?view=long&pmid=32098829
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682371/
- https://pubmed.ncbi.nlm.nih.gov/27872096/
Pubmed Page
Email Address for application
Biography
Dr. Stagg received his PhD from McGill University and pursued postdoctoral training in immuno-oncology in Melbourne, Australia from 2005 to 2010. Dr. Stagg’s work has identified the CD73-adenosine axis as a novel therapeutic target in immuno-oncology, leading to the development of targeted therapies currently in clinical trials. Dr. Stagg is a Canadian Institutes of Health Research Scholar and co-holder of the Jean-Guy Sabourin Pharmaceutical Chair in Women’s Health at the Université de Montréal.
Related research
